Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations. Its product pipeline consists of COM701, a monoclonal antibody designed to block the interaction of PVRIG with its cognate ligand, PVRL2; CGEN-15001T, an immuno-oncology therapeutic program for ILDR2; and COM902, a therapeutic antibody candidate for its TIGIT program. The company's pipeline also comprises therapeutic proteins include CGEN-15001, a fusion protein drug candidate for autoimmune diseases, including extracellular domain of ILDR2 and an IgG Fc domain. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CGEN
CUSIPN/A
Phone972-3765-8585
Debt
Debt-to-Equity RatioN/A
Current Ratio5.81
Quick Ratio5.81
Price-To-Earnings
Trailing P/E Ratio-4.65
Forward P/E Ratio-7.44
P/E GrowthN/A
Sales & Book Value
Annual Sales$710,000.00
Price / Sales242.00
Cash FlowN/A
Price / CashN/A
Book Value$0.57 per share
Price / Book5.88
Profitability
EPS (Most Recent Fiscal Year)($0.72)
Net Income$-37,060,000.00
Net MarginsN/A
Return on Equity-78.00%
Return on Assets-62.61%
Miscellaneous
Employees101
Outstanding Shares51,290,000
Market Cap$173.11
Compugen (NASDAQ:CGEN) Frequently Asked Questions
What is Compugen's stock symbol?
Compugen trades on the NASDAQ under the ticker symbol "CGEN."
How were Compugen's earnings last quarter?
Compugen Ltd. (NASDAQ:CGEN) announced its quarterly earnings data on Tuesday, August, 2nd. The biotechnology company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.04. The biotechnology company had revenue of $0.50 million for the quarter, compared to the consensus estimate of $0.11 million. View Compugen's Earnings History.
When is Compugen's next earnings date?
What price target have analysts set for CGEN?
2 Wall Street analysts have issued 1-year price objectives for Compugen's shares. Their forecasts range from $9.00 to $9.00. On average, they anticipate Compugen's share price to reach $9.00 in the next year. This suggests a possible upside of 168.7% from the stock's current price. View Analyst Ratings for Compugen.
What is the consensus analysts' recommendation for Compugen?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Compugen's key competitors?
Some companies that are related to Compugen include CASI Pharmaceuticals (CASI), Mesoblast (MESO), Voyager Therapeutics (VYGR), BioCryst Pharmaceuticals (BCRX), Fate Therapeutics (FATE), Nightstar Therapeutics (NITE), Novavax (NVAX), Vericel (VCEL), PDL BioPharma (PDLI), Scholar Rock (SRRK), Cellular Biomedicine Group (CBMG), Surface Oncology (SURF), Osiris Therapeutics (OSIR), Adverum Biotechnologies (ADVM) and NanoString Technologies (NSTG).
Who are Compugen's key executives?
Compugen's management team includes the folowing people:
- Dr. Anat Cohen-Dayag, Chief Exec. Officer, Pres and Director (Age 51)
- Mr. Ari Krashin, Chief Financial and Operating Officer (Age 45)
- Mr. Kirk A. Christoffersen MBA, Sr. VP of Corp. and Bus. Devel. (Age 49)
- Dr. Zurit Levine Ph.D., VP of Research & Discovery (Age 50)
- Dr. John J. Hunter, VP of Antibody R&D (Age 55)
Has Compugen been receiving favorable news coverage?
News stories about CGEN stock have trended somewhat positive this week, according to Accern. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Compugen earned a news impact score of 0.14 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 45.86 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are Compugen's major shareholders?
Which institutional investors are buying Compugen stock?
How do I buy shares of Compugen?
Shares of CGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Compugen's stock price today?
One share of CGEN stock can currently be purchased for approximately $3.35.
How big of a company is Compugen?
Compugen has a market capitalization of $173.11 million and generates $710,000.00 in revenue each year. The biotechnology company earns $-37,060,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. Compugen employs 101 workers across the globe.
How can I contact Compugen?
Compugen's mailing address is AZRIELI CENTER 26 HAROKMIM STREET BUILDING D, HOLON L3, 5885849. The biotechnology company can be reached via phone at 972-3765-8585 or via email at [email protected]
MarketBeat Community Rating for Compugen (NASDAQ CGEN)
MarketBeat's community ratings are surveys of what our community members think about Compugen and other stocks. Vote "Outperform" if you believe CGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
